The Global Point-of-Care Molecular Diagnostics Market is projected to grow at a CAGR of 10.2% from 2026 to 2033, according to a new report published by Verified Market Reports®. The report reveals ...

Myriad Genetics and Lumea Inc. partner to integrate molecular diagnostics into Lumea's digital pathology platform, enhancing cancer care efficiency. Myriad Genetics and Lumea Inc. have announced a ...

"Driven by Advances in Genetic and Cancer Testing, Molecular Diagnostics Emerges as a Critical Tool for Early Disease Detection and Risk Prediction"Boston, Oct. 22, 2025 (GLOBE NEWSWIRE) -- According ...

SALT LAKE CITY and BOSTON, Sept. 23, 2025 /PRNewswire/ -- Myriad Genetics (MYGN) (Nasdaq: MYGN), a leader in molecular diagnostic testing and precision medicine, and SOPHiA GENETICS (SOPH) (Nasdaq: ...

Myriad Genetics ( ($MYGN) ) has released its Q3 earnings. Here is a breakdown of the information Myriad Genetics presented to its investors.

All authors are employees of the UnitedHealth Group. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial ...

This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer .

Breast cancer detection has evolved from microscopes to molecular precision to offer diagnostic insights: Expert: Shardul Nautiyal, Mumbai Saturday, November 1, 2025, 08:00 Hrs [I ...

The Rising Wave of Esoteric Testing The Esoteric Testing Market represents a specialized segment of diagnostic laboratory services that focuses on rare and complex tests not routinely performed in ...

Labroots is excited to announce our 14th Annual Precision Medicine: Genomics, Genetics & Molecular Diagnostics Virtual Event Series 2026 held on May 13th, 2026! The Precision Medicine: Genomics, ...